Simulations Plus Releases DDDPlus Version 5.0

Keywords: in vitro dissolution experiment simulation software, pharmaceutical dosage forms
Software: DDDPlus™
Division: PBPK

Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has released Version 5.0 of its DDDPlus™ in vitro dissolution experiment simulation software.

Mr. Jim Mullin, product manager for DDDPlus at Simulations Plus, said: “We’re very pleased to announce the release of DDDPlus Version 5.0. This upgrade further extends our lead in this area by adding valuable new functionalities that will enable formulation scientists in both innovator and generic companies, as well as regulatory agencies, to gain insight into the behaviors of various formulations for pharmaceutical dosage forms. Several of the significant enhancements include:

  • integration of the optional add-on ADMET Predictor™ Module
  • simulation of in vitro dissolution of coated bead, coated tablet, and bilayer tablet dosage forms
  • addition of tablet disintegration and porosity models
  • expanded library of dissolution apparatus to include the Pion ?DISS Profiler™ experiment
  • improved 3D Parameter Sensitivity Analysis mode.”

Mr. John DiBella, vice president for marketing and sales for Simulations Plus, added: “When we first released DDDPlus about ten years ago, acceptance was slower than we expected, primarily because the industry did not have any experience with such a tool. Now the program is in use in pharmaceutical companies and regulatory agencies worldwide, and we receive and respond to customer requests to continue to enhance its capabilities. Also, we have begun promoting synergies between DDDPlus and our flagship GastroPlus™ program to assist with formulation optimization, as we believe there is an opportunity to leverage the large GastroPlus user base to drive further adoption of DDDPlus. In addition to the enhancements in version 5.0 that we are announcing today, we are already at work on further expanding the scope of DDDPlus simulations to include long-acting injectable microspheres as part of one of our funded research collaboration agreements with the U.S. Food and Drug Administration.”